Product Description
A hormone made from testosterone in the prostate, testes, and certain other tissues. It is needed to develop and maintain male sex characteristics, such as facial hair, deep voice, and muscle growth. High amounts of androstanolone may increase the growth of prostate cancer and make it harder to treat. Also called DHT and dihydrotestosterone. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/androstanolone)
Mechanisms of Action: AR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Transdermal, Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: France | India | Slovenia | Taiwan | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Ascend
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hypogonadism|Prostate Cancer|Bone Cancer|Hypothalamic Cancer|Pituitary Diseases|Inflammation|Deficiency Diseases|Breast Cancer|Bladder Cancer|Hypopituitarism|Skin Cancer|Hypothalamic Diseases|Pregnancy Outcomes|Pituitary Cancer|Protein Deficiency|Vascular Cancer|Skin Diseases, Vascular|Testicular Diseases|Prostatic Hyperplasia|Testicular Cancer|Prostatic Diseases
Phase 1: Prostate Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01724619 |
IRB00015971 | P1 |
Terminated |
Prostate Cancer |
2013-03-01 |
2019-03-19 |
||
2014-005684-32 |
FDHT - version 1, 9 March 2015 | P2 |
Terminated |
Prostate Cancer |
2018-09-15 |
2022-03-13 |
Treatments |
|
2013-002415-10 |
[18F]FDHT PET in hormone naive prostate cancer | P2 |
Active, not recruiting |
Prostate Cancer|Bone Cancer |
2016-02-11 |
2022-03-13 |
Treatments |
|
2012-003981-42 |
2012-003981-42 | P2 |
Completed |
Breast Cancer |
2015-05-13 |
2025-07-09 |
Treatments |
|
NCT00490022 |
DHT-3 | P2 |
Completed |
Pituitary Cancer|Skin Diseases, Vascular|Bladder Cancer|Hypothalamic Cancer|Testicular Diseases|Inflammation|Protein Deficiency|Pregnancy Outcomes|Hypogonadism|Vascular Cancer|Deficiency Diseases|Skin Cancer|Prostate Cancer|Pituitary Diseases|Hypopituitarism|Prostatic Hyperplasia|Testicular Cancer|Prostatic Diseases|Hypothalamic Diseases |
2009-01-01 |
2019-03-21 |
Treatments |
|
NCT00163566 |
03-DHT-01 | P2 |
Completed |
Hypogonadism |
2006-09-01 |
2022-08-16 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |